A national reference for inactivated polio vaccine derived from Sabin strains in Japan

Vaccine

Volumn 32, Issue 40, 2014, Pages 5163-5169

  Shirato, Haruko ^a   Someya, Yuichi ^a   Ochiai, Masaki ^a   Horiuchi, Yoshinobu ^a   Takahashi, Motohide ^a   Takeda, Naokazu ^a   Wakabayashi, Kengo ^b   Ouchi, Yasumitsu ^b   Ota, Yoshihiro ^b   Tano, Yoshio ^b   Abe, Shinobu ^b   Yamazaki, Shudo ^b   Wakita, Takaji ^a   Shimoike, Takashi ^c   Oka, Tomoichiro ^c   Murakami, Kosuke ^c   Fujii, Yoshiki ^c   Park, YoungBin ^c   Takai Todaka, Reiko ^c   Miyamura, Tatsuo ^c   Shimizu, Hiroyuki ^c   Katayama, Kazuhiko ^c   more..

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Japan Poliomyelitis Research Institute   (Japan)

^c Department of Bacterial Pathogenesis and Infection Control National Institute of Infectious Diseases ^*

Author keywords

Inactivated polio vaccine; National reference vaccine; Poliomyelitis; Sabin strain

Indexed keywords

INACTIVATED POLIO VACCINE; NEUTRALIZING ANTIBODY; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; FEMALE; GROWTH CURVE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; JAPAN; MALE; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; QUALITY CONTROL; RAT; SEROTYPE; TETANUS; VIRUS STRAIN; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; ANIMAL; BLOOD; CLASSIFICATION; IMMUNOLOGY; POLIOMYELITIS VIRUS; STANDARDS; WISTAR RAT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; JAPAN; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; RATS, WISTAR; SEROGROUP; VACCINE POTENCY;

EID: 84906065707     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.065     Document Type: Article

References (28)

1. Bodian D. Emerging concept of poliomyelitis infection. Science 1955, 122:105-108.
2. Sabin A.B. Pathogenesis of poliomyelitis: reappraisal in the light of new data. Science 1956, 123:1151-1157.
3. WHO. The global polio eradication on initiative. http://www.polioeradication.org/Dataandmonitoring.aspx.
4. Hao L., Toyokawa S., KobayashiF Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis 2008, 61:100-103.
5. Sutter R.W., Kew O.M., Cochi S.L. Poliovirus vaccine-live. Vaccines 2008, 631-685. Saunders Elsevier. 5th ed. S.A. Plotkin, W.A. Orenstein, P. Offit (Eds.).
6. WHO. Polio eradication & endgame strategic plan 2013-2018. http://www.polioeradication.org/resourcelibrary/strategyandwork.aspx.
7. WHO global action plan to minimize poliovirus facility-associated risk after eradication of wild polioviruses and cessation of routine OPV use. http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/GAP3_2009.pdf.
8. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006, 34:155-158.
9. Bakker W.A., Thomassen Y.E., van't Oever A.G., Westdijk J., van Oijen M.G.C.T., Sundermann L.C., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29:7188-7196.
10. Murph J.R., Grose C., McAndrew P., Mickiewicz C., Mento S., Cano F., et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 1988, 7:760-765.
11. Doi Y., Abe S., Yamamoto H., Horie H., Ohyama H., Satoh K., et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001, 105:163-169.
12. Westdijk J., Brugmans D., Martin J., van't Oever A., Bakker W.A.M., Levels L., et al. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2001, 29:3390-3397.
13. Verdijk P., Rots N.Y., Bakker W.A. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011, 10:635-644.
14. Verdijk P., Rots N.Y., van Oijen M.G., Obersteb M.S., Boog C.J., Okayasu H., et al. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine 2013, 31:5531-5536.
15. Simizu B., Abe S., Yamamoto H., Tano Y., Ota Y., Miyazawa M., et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006, 34:151-154.
16. Wood D.J., Heath A.B., Kersten G.F., Hazendonk T., Lantinga M., Beuvery E.C. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine. Biologicals 1997, 25:59-64.
17. WHO Technical Working Group Meeting on Revision of the WHO Recommendations for the Production and Control of Inactivated Poliomyelitis Vaccines: TRS No. 910, Annex 1. http://www.who.int/biologicals/areas/vaccines/IPV_Meeting_TRS_Revision_14-15_May_2013_Report_FINAL_22112013.pdf.
18. van Wezel A.L., van Steenis G., Hannik C.A., Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 1978, 41:159-168.
19. Tano Y., Shimizu H., Martin J., Nishimura Y., Simizu B., Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25:7041-7046.
20. Finney D.J. Statistical methods in biological assay 1978, Charles Griffin Co. Ltd., London. 3rd ed.
21. Wood D.J., Heath A.B., Sawyer L.A. A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals 1995, 23:83-94.
22. Wood D.J., Heath A.B. A WHO collaborative study on assays of immunogenicity assays of inactivated poliovirus vaccines. Biologicals 1995, 23:301-311.
23. World Health Organization Requirements for poliomyelitis vaccine (inactivated). WHO technical report series 2002, vol. 910:32-65.
24. van Steenis G., van Wezel A.L., Sekhuis V.M. Potency testing of killed polio vaccine in rats. Dev Biol Stand 1981, 47:119-128.
25. Cohen A.C. Simplified estimators for the normal distribution when samples are singly censored or truncated. Technometrics 1959, 1:217-237.
26. Tsay J.Y., Chen I.W., Maxon H.R., Heminger L. A statistical method for determining normal ranges from laboratory data including values below the minimum detectable value. Clin Chem 1979, 25:2011-2014.
27. Okada K., Miyazaki C., Kino Y., Ozaki T., Hirose M., Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis 2013, 208::275-283.
28. Liao G., Li R., Li C., Sun M., Li Y., Chu J., et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012, 205:237-243.